Targeted SLNs for management of HIV-1 associated dementia

Nand, Akhila; Jain, Ankit; Jain, Ashish; Jain, Aviral; Pandey, Vikas; Chashoo, Gousia; Soni, Vandana; Sharma, Parveen

doi:10.3109/03639045.2014.948453

Cited by 16 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…on the luminal side of the BBB and degrading ecto-or endo-enzymes of the cytoplasm of endothelial cells prior to penetration into the brain (12). SLNs composed of biodegradable saturated lipids like HSPC are found to be biocompatible (13,14) and prolong blood circulation life because of enhanced in vivo stability (15,16). Pioneering characteristics of SLNs also extend many advantages such as controlled drug release (17), drug targeting and low biotoxicity, high drug payload, easy scale up, and amenability to sterilization (18,19).…”

Section: Introductionmentioning

confidence: 98%

Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis

Devi¹,

Jain²,

Hurkat³

et al. 2015

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis

Devi¹,

Jain²,

Hurkat³

et al. 2015

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Polysorbate 80 also facilitated the transport of DOX-SLN across the BBB through receptor-mediated endocytosis. [7,19] For both the formulations, survival fraction of cells was found to be inversely dependent on the concentration of the drug [ Figure 5a]. Figure 5b also confirmed the higher toxicity of DOX-SLN than a plain drug as the number of U87MG cells in the photomicrograph of DOX-SLN was found to be less than the plain drug.…”

Section: Resultsmentioning

confidence: 57%

Untitled

Soni¹

2019

AJP

View full text Add to dashboard Cite

Introduction: Primary brain tumors are the tumors that grow within the brain from the brain cells. The treatment of primary brain tumor is the biggest challenge in the field of oncology due to the presence of blood-brain barrier (BBB). The BBB prevents the entry of most of the drugs inside brain cells from the blood. Therefore, the present work was intended to develop and investigate the ability of polysorbate 80 coated solid lipid nanoparticles (SLN) to deliver doxorubicin (DOX) in the brain for the treatment of brain cancer cells. Materials and Methods: The polysorbate 80 coated, DOX loaded-SLN (DOX-SLN) were prepared by the solvent evaporation method using a mixture of tristearin, hydrogenated soy phosphatidylcholine, and cholesterol lipids. DOX-SLN were characterized for various attributes such as average particle size, size distribution, zeta potential, surface morphology, entrapment efficiency, drug release, cytotoxicity, and cellular uptake studies. Cytotoxicity and cellular uptake studies were performed on U87MG brain cancer cell lines. Results and Discussion: DOX-SLN prepared by solvent evaporation method possesses an average particle size near 200 nm and polydispersity index (PDI) below 0.3. The zeta potential of the prepared nanoparticles was found to be -14 mV with 45.3 ± 0.2% entrapment efficiency. The cytotoxicity studies showed the higher toxicity of DOX-SLN than plain DOX on U87MG cell lines. The cellular uptake studies also confirmed the internalization of the DOX-SLN inside brain cancer cells. Conclusions: The results confirmed the development of a potential carrier for brain cancer treatment with enhanced ability to cross the BBB.

show abstract

“…Site-specific drug delivery, excellent biocompatibility, high stability, high drug entrapment with customizable particle size, high surface-to-volume ratio, low manufacturing cost, etc. make SLNs attractive carriers for ophthalmic drug delivery [ 125 , 126 ]. The hydrophobic system of lipid molecules interacts with water, causing self-assembly of lipids through liposome formation.…”

Section: Applications Of Nano-based Materials For Ocular Drug Deliverymentioning

confidence: 99%

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

2022

View full text Add to dashboard Cite

Ocular drug delivery is one of the most challenging endeavors among the various available drug delivery systems. Despite having suitable drugs for the treatment of ophthalmic disease, we have not yet succeeded in achieving a proper drug delivery approach with the least adverse effects. Nanotechnology offers great opportunities to overwhelm the restrictions of common ocular delivery systems, including low therapeutic effects and adverse effects because of invasive surgery or systemic exposure. The present review is dedicated to highlighting and updating the recent achievements of nano-based technologies for ocular disease diagnosis and treatment. While further effort remains, the progress illustrated here might pave the way to new and very useful ocular nanomedicines.

show abstract

Targeted SLNs for management of HIV-1 associated dementia

Abstract: Tween 80 enhanced localization of SLNs in the brain as compared to uncoated SLNs. This approach can be employed effectively to transport chemotherapeutics across the BBB for management of HIV-1 associated dementia and other ailments.

Cited by 16 publications

References 27 publications

Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis

Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis

Untitled

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

Contact Info

Product

Resources

About